Loading...
TRIB2 contributes to cisplatin resistance in small cell lung cancer
Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most important components among all standard poly-chemotherapeutic regimens for SCLC; therefore, this study fo...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5752545/ https://ncbi.nlm.nih.gov/pubmed/29312632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22741 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|